Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control of Symptoms Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

NCT03325881
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 30, 2026, 10:08 AM EDT
Withdrawn Phase 4 Interventional

Prophylactic Analgesia for Bladder Botox Injections

NCT06514430
View directory record Official record
Conditions
Urinary Incontinence, Urinary Incontinence, Urge, Overactive Bladder
Interventions
Phenazopyridine, 1% lidocaine with sodium bicarbonate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Utility of Nexium in Chronic Cough and Reflux Disease

NCT00287339
View directory record Official record
Conditions
Cough, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

NCT00568594
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

NCT00401830
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
25
States / cities
Litchfield Park, Arizona • Santa Ana, California • Walnut Creek, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 30, 2026, 10:08 AM EDT
Recruiting Not applicable Interventional

A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma

NCT05910567
View directory record Official record
Conditions
Blunt Trauma to Abdomen, Wounds and Injuries, Abdomen Injury, Abdominal Injury, Abdomen, Acute
Interventions
Focused Assessment with Sonography for Trauma (FAST) Examination, No Intervention: Standard of Care - Without the FAST Examination
Diagnostic Test · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 17 Years
Enrollment
4,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

NCT06940154
View directory record Official record
Conditions
COPD Acute Exacerbation
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Not applicable Interventional Results available

Contralaterally Controlled FES of Arm & Hand for Subacute Stroke Rehabilitation

NCT01688856
View directory record Official record
Conditions
Stroke, Hemiparesis, Hemiplegia
Interventions
Electrical Stimulator
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Benefits of Outdoor Walks in Reducing Depressive Symptoms

NCT06989801
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Urban Walk, Nature Walk, Active Nature Walk
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications

NCT00796822
View directory record Official record
Conditions
HIV, Cardiovascular Diseases, Atherosclerosis
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 30, 2026, 10:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

NCT04004325
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
Interventions
FT-4101, FT-4101 placebo, Deuterated Water
Drug · Other
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Chula Vista, California • Montclair, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

NCT03347708
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT, Saline Solution, Sodium Hyaluronate
Biological · Drug
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Not applicable Interventional

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

NCT00287235
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Failure, Hepatitis, Chronic, Liver Cirrhosis
Interventions
MARS, Standard Medical Therapy
Device · Drug
Lead sponsor
Vantive Health LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 30, 2026, 10:08 AM EDT
Terminated Not applicable Interventional

Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301

NCT02211508
View directory record Official record
Conditions
Fibromyalgia
Interventions
RINCE
Device
Lead sponsor
Cerephex Corporation
Industry
Eligibility
22 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Napa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis

NCT00656890
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
sterile saline for injection, MDX-1100
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Port Orange, Florida • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Sep 30, 2026, 10:08 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

NCT03793010
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
FX006, Normal saline
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Sep 30, 2026, 10:08 AM EDT
Not listed Not applicable Interventional

Neuroma Injections to Treat Restless Legs Syndrome - RCT

NCT00656110
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml, Normal saline - 1ml
Drug
Lead sponsor
Lowcountry Infectious Diseases
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2009 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

NCT04462198
View directory record Official record
Conditions
Sensorineural Hearing Loss
Interventions
PIPE-505, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Torrance, California • Boca Raton, Florida • New Albany, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 30, 2026, 10:08 AM EDT
Terminated Not applicable Interventional

Oral Carnitine for Cramps in Pregnancy

NCT00516516
View directory record Official record
Conditions
Muscle Cramp
Interventions
L-Carnitine, Placebo
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

NCT02975206
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Serlopitant High Dose, Placebo Oral Tablet, Serlopitant Low Dose
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
13 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 44 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Not applicable Interventional Results available

Continuous Subpleural Infusion of Bupivacaine

NCT01566838
View directory record Official record
Conditions
Postoperative Pain
Interventions
Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 30, 2026, 10:08 AM EDT
Completed Phase 4 Interventional Results available

Labetalol and Esmolol: Vital Signs and Post Operative Pain Management

NCT01114971
View directory record Official record
Conditions
Laparoscopic Surgery
Interventions
Fentanyl, Labetalol, Esmolol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 30, 2026, 10:08 AM EDT